1.
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
by Martins, Filipe
The lancet oncology, 2019-01, Vol.20 (1), p.e54-e64
2.
The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017
by Neal, Joseph M
Regional anesthesia and pain medicine, 2018-02, Vol.43 (2), p.113-123
3.
The American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2017 Version
by Neal, Joseph M
Regional anesthesia and pain medicine, 2018-02, Vol.43 (2), p.150-153
4.
The Mechanisms Underlying Lipid Resuscitation Therapy
by Fettiplace, Michael R
Regional anesthesia and pain medicine, 2018-02, Vol.43 (2), p.138-149
5.
The prescribing cascade revisited
by Rochon, Paula A
The Lancet (British edition), 2017, Vol.389 (10081), p.1778-1780
6.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled tri...
by Park, Keunchil, Prof
The lancet oncology, 2016, Vol.17 (5), p.577-589
7.
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
by Auslander, Noam
Nature medicine, 2018-10, Vol.24 (10), p.1545-1549
8.
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
by Corsello, Salvatore Maria
The journal of clinical endocrinology and metabolism, 2013-04, Vol.98 (4), p.1361-1375
9.
Exploring and comparing adverse events between PARP inhibitors
by LaFargue, Christopher J
The lancet oncology, 2019-01, Vol.20 (1), p.e15-e28
10.
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
by Bachelot, Thomas, Dr
The lancet oncology, 2013, Vol.14 (1), p.64-71
11.
Local Anesthetic Systemic Toxicity: A Review of Recent Case Reports and Registries
by Gitman, Marina
Regional anesthesia and pain medicine, 2018-02, Vol.43 (2), p.124-130
12.
Adverse drug reactions: definitions, diagnosis, and management
by Edwards, I Ralph
The Lancet (British edition), 2000-10-07, Vol.356 (9237), p.1255-1259
13.
Local Anesthetic Systemic Toxicity in Total Joint Arthroplasty: Incidence and Risk Factors in the United States From the National Inpatient Sample 1998–2013
by Rubin, Daniel S
Regional anesthesia and pain medicine, 2018-02, Vol.43 (2), p.131-137
14.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
by Abou-Alfa, Ghassan K
The lancet oncology, 2020-05, Vol.21 (5), p.671-684
15.
Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects
by Dolder, Patrick C
Psychopharmacology, 2017-05-27, Vol.235 (2), p.467-479
16.
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
by Fellay, Jacques
The Lancet (British edition), 2001, Vol.358 (9290), p.1322-1327
17.
Drug-induced acid-base disorders
by Kitterer, Daniel
Pediatric nephrology (Berlin, West), 2014-11-05, Vol.30 (9), p.1407-1423
18.
Vaccine safety evaluation: Practical aspects in assessing benefits and risks
by Di Pasquale, Alberta
Vaccine, 2016, Vol.34 (52), p.6672-6680
19.
20.
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an...
by Mizokami, Masashi, Prof
The Lancet infectious diseases, 2015, Vol.15 (6), p.645-653
